Method for down-regulation of vegf
AssigneePharmexa A/S
InventorsPeter Rasmussen, Florence Dal Degan, Valery Renard, Steen Klysner, Birgitte Volck
Life of this patent
Estimating the term…
Abstract
The present invention provides for novel immunogenic variants of VEGF (vascular endothelial growth factor) which are useful in active specific immunotherapy against diseases that are characterized by overexpression of VEGF. The invention also relates to methods of treating such diseases (for instance cancer) as well as to various tools in molecular biology that assist in the provision of the immunogenic variants.
Claims64
A method for in vivo down-regulation of Vascular Endothelial Growth Factor (VEGF) activity in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of
- at least one autologous VEGF protein or an autologous VEGF polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the VEGF protein or VEGF polypeptide or subsequence thereof induces production of antibodies the animal's autologous VEGF protein, and/or
- at least one VEGF analogue, which comprises a VEGF polypeptide wherein is introduced at least one modification in the VEGF amino acid sequence which has as a result that immunization of the animal with the analogue induces production of antibodies against the animal's autologous VEGF protein.
An immunogenic composition comprising an immunogenically effective amount of a VEGF polypeptide autologous in an animal, said VEGF polypeptide being formulated together with an immunologically acceptable adjuvant so as to break the animal's autotolerance towards the VEGF polypeptide, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle.
Dependencies are inferred from the claim text.